M&A / Deals Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout BioPharma DiveThe deal secures two sleep disorder drugs that would fill a hole in the company s portfolio and intensify a competition with Takeda and Eisai.M&A / DealsNeuroscienceRead full story pharminent March 31, 2026 (Last updated: April 1, 2026) BioPharma Dive The deal secures two sleep disorder drugs that would fill a hole in the company s portfolio and intensify a competition with Takeda and Eisai. M&A / DealsNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis BuyNext: Novo hits back at rivals with cut-price Wegovy subscriptions Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
